Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-bioMatch: Biomarker-targeted Treatment in CKD
NCT07239570Phase 4Recruiting
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin, finerenone and semaglutide in chronic kidney disease (CKD) (2 arms). Primary endpoint: Chronic estimated glomerular filtration rate slope. Started Jun 2025; status: recruiting.
02
Drugs
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07239570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239570.